Literature DB >> 3978363

Peripheral joint involvement in polymyalgia rheumatica: a clinical study of 56 cases.

A S Al-Hussaini, A J Swannell.   

Abstract

A follow-up study of 56 patients with the provisional diagnosis of polymyalgia rheumatica showed that 12 developed peripheral synovitis during the course of the illness. Five of the 12 were noted to have synovitis on presentation which was characteristically mild, pauci-articular and cleared quickly after commencing prednisolone therapy. The remaining seven had persistent synovitis of peripheral small joints despite an initial brisk response to oral prednisolone. Five of these patients were found to satisfy the ARA criteria for rheumatoid arthritis after a mean follow-up period of 3.5 years. It is suggested that the persistence of peripheral synovitis in patients treated as polymyalgia rheumatica should alert the clinician to the possible development of rheumatoid arthritis.

Entities:  

Mesh:

Year:  1985        PMID: 3978363     DOI: 10.1093/rheumatology/24.1.27

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  4 in total

1.  Giant cell arteritis precipitated by a diagnostic trial of prednisolone in suspected polymyalgia rheumatica.

Authors:  P A Reilly; P J Maddison
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

2.  Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study.

Authors:  R Caporali; C Montecucco; O Epis; F Bobbio-Pallavicini; T Maio; M A Cimmino
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 3.  Polymyalgia rheumatica. Its correct diagnosis and treatment.

Authors:  F D Hart
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

Review 4.  Diagnosis of polymyalgia rheumatica usually means a favourable outcome for your patient.

Authors:  Marcin Milchert; Marek Brzosko
Journal:  Indian J Med Res       Date:  2017-05       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.